Meta-Analysis of Paediatric Patients with Central Precocious Puberty Treated with Intramuscular Triptorelin 11.25 mg 3-Month Prolonged-Release Formulation

Abstract

Background/Aims: A meta-analysis was undertaken to assess the effect of triptorelin 11.25 mg 3-month prolonged-release formulation in central precocious puberty (CPP). Methods: All available clinical studies with triptorelin 11.25 mg were included. The primary outcome was the proportion of children with suppressed luteinising hormone (LH) response (peak LH ≤3 IU/L) to the gonadotrophin-releasing hormone (GnRH) test 3 months after triptorelin 11.25 mg injection. Secondary outcomes included: the proportion with suppressed peak LH response at 6 months and the proportion with suppressed peak follicle-stimulating hormone (FSH) response (≤3 IU/L), suppressed oestradiol (≤20 pmol/L) in girls or suppressed testosterone (≤30 ng/dL) in boys at 3 months. Results: 153 children (13 boys, 140 girls) were included. The proportion with a suppressed peak LH response to the GnRH test was 87.6% (95% CI: 81.3–92.4, p < 0.0001, for a proportion >70%) and 92.8% (95% CI: 87.5–96.4, p < 0.0001, for a proportion >70%) at 3 and 6 months, respectively. FSH peak, oestradiol, and testosterone were suppressed in 86.7% (95% CI: 79.1–92.4), 97.1% (95% CI: 91.6–99.4), and 72.7% (95% CI: 39.0–94.0) of children at 3 months, respectively. Conclusion: Triptorelin 11.25 mg 3-month formulation is efficacious in suppressing LH peak and other gonadal hormones and in slowing the progression of CPP in children.

Puberty in the Last 25 Years: A Retrospective Bibliometric Analysis

“…Meta‐analyses may have been missed by our search strategy for this particular analysis (which was not a systematic review). A positive note is that meta‐analyses on puberty are continually being published (e.g., Bertelloni, Massart, Miccoli, & Baroncelli, ; Deng et al., ; Durand, Tauber, Patel, & Dutailly, ; Li et al., ; Ullsperger & Nikolas, ). Given the breadth and quantity of research on puberty, meta‐analyses will continue to be particularly useful for synthesizing the literature on puberty in the future.…”

Update on central precocious puberty: from etiologies to outcomes

“…Three-monthly depot preparations, also administered via intramuscular injection, have also been used to treat CPP, particularly in Europe [51]. Several studies as well as a meta-analysis have suggested that the degree of biochemical suppression achieved with 3-monthly dosing is consistently less than that seen with monthly GnRHa administration [51][52][53][54]. However, the clinical response to treatment appears to be similar based on limited data.…”

Central precocious puberty: From genetics to treatment

“…Three-monthly depot preparations, also administered via intramuscular injection, have also been used to treat CPP [44]. Several studies have suggested that the degree of biochemical suppression achieved with 3-monthly dosing is consistently less than that seen with monthly GnRHa administration [1, 42,[44][45][46][47]. Nonetheless, the clinical response to treatment appears to be equivalent although minimal comparative information is available.…”